Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies

Michael W. Baughn, Ze'ev Melamed*, Jone López-Erauskin, Melinda S. Beccari, Karen Ling, Aamir Zuberi, Maximilliano Presa, Elena Gonzalo-Gil, Roy Maimon, Sonia Vazquez-Sanchez, Som Chaturvedi, Mariana Bravo-Hernández, Vanessa Taupin, Stephen Moore, Jonathan W. Artates, Eitan Acks, I. Sandra Ndayambaje, Ana R. Agra de Almeida Quadros, Paayman Jafar-Nejad, Frank RigoC. Frank Bennett, Cathleen Lutz, Clotilde Lagier-Tourenne*, Don W. Cleveland*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


Loss of nuclear TDP-43 is a hallmark of neurodegeneration in TDP-43 proteinopathies, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). TDP-43 mislocalization results in cryptic splicing and polyadenylation of pre-messenger RNAs (pre-mRNAs) encoding stathmin-2 (also known as SCG10), a protein that is required for axonal regeneration. We found that TDP-43 binding to a GU-rich region sterically blocked recognition of the cryptic 3' splice site in STMN2 pre-mRNA. Targeting dCasRx or antisense oligonucleotides (ASOs) suppressed cryptic splicing, which restored axonal regeneration and stathmin-2-dependent lysosome trafficking in TDP-43-deficient human motor neurons. In mice that were gene-edited to contain human STMN2 cryptic splice-polyadenylation sequences, ASO injection into cerebral spinal fluid successfully corrected Stmn2 pre-mRNA misprocessing and restored stathmin-2 expression levels independently of TDP-43 binding.

Original languageAmerican English
Pages (from-to)1140-1149
Number of pages10
Issue number6637
StatePublished - 17 Mar 2023

Bibliographical note

Funding Information:
This work was supported by NINDS/NIH R01NS112503 (to D.W.C. and C.L.-T.); NINDS/NIH RF1NS124203 (D.W.C., C.L.-T., and C.L.); ALS Finding a Cure (C.L.-T.); The Massachusetts Center for Alzheimer Therapeutic Science (C.L.-T.); The Sean M. Healey & AMG Center for ALS at Mass General (C.L.-T.); U42 Mutant Mouse Resource Research Center OD010921 (C.L.); Ruth Kirschstein Institutional National Research Service Award T32 GM008666. (M.W.B. and M.S.B.), and T32 AG 66596-2 (M.S.B.); The Packard Center for ALS Research (D.W.C. and M.W.B.); The ALS association (D.W.C., M.W.B., and S.V.-S.); MDA development grants (Z.M. and J.L.-E.); The BrightFocus Foundation (A.R.A.d.A.Q.); and Cancer Center Support Grant CA034196 to The Jackson Laboratory.

Funding Information:
For ultrastructural characterization of excitatory synaptic terminals, ASO treated human motor neurons were fixed for 1 hour with 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer, pH 7.4, and spun down to a cell pellet. Subsequently, the pellet was blocked with 1% osmium tetroxide in 0.15 M sodium cacodylate buffer (LADD Research), stained with 2% uranyl acetate in double distilled water (LADD Research), and dehydrated with ethanol (LADD Research). The cells were then embedded in Durcupan resin (Sigma) and sectioned on an Ultracut UC6 Ultramicrotome (Leica) by using a diamond knife (Diatome). The sections were next transferred onto copper mesh grids (LADD Research) and post-stained with uranyl acetate and lead citrate (Electron Microscopy Sciences). Images were acquired using a JEOL1400 (JEOL, Peabody, MA) transmission electron microscope (supported by NIH equipment grant 1S10OD023527-01) at 80kV using a Oneview 4KGatan digital camera (Gatan, Pleasanton, CA).

Publisher Copyright:
Copyright © 2023 The Authors, some rights reserved.


Dive into the research topics of 'Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies'. Together they form a unique fingerprint.

Cite this